Miraca Life Sciences

Serving more than 3,000 patients each day, Miraca Life Sciences is a leader in providing academic-caliber pathology services in the fields of dermatopathology, GI pathology, hematopathology and urologic pathology.

We employ a talented team of leading pathologists, histologists, molecular pathology experts, lab technicians and other medical professionals. Our commitment to scientific excellence drives our hiring decisions and informs everything we do.

Miraca Life Sciences is a subsidiary of Miraca Holdings, Inc., Japan’s largest clinical diagnostics and laboratory testing service provider. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012.

Services by Specialty

Dermatology

Gastroenterology

Hematology

Urology

FOR CARIS TARGET NOW^™
AND CARISOME^™

Caris Target Now Molecular Profiling and Carisome Circulating Microvesicle Technology are owned by Caris Life Sciences, Ltd.

Information about these innovative technologies can be found at CarisLifeSciences.com.

Recent News

Caris Diagnostics Announces Name Change to Miraca Life Sciences

Caris Diagnostics, specializing in academic-caliber anatomic pathology services, today announced a company name change to Miraca Life Sciences, following its November 2011 acquisition by Tokyo-based Miraca Holdings, Inc. The name change will be effective February 20, 2012.
Read more.

Caris AP Business Joins Miraca Holdings

Caris Life Sciences' anatomic pathology business and its subsidiaries and affiliates (operated by Caris Diagnostics, Inc.) is now officially part of Miraca Holdings, Inc.
Read more.

More about Miraca Holdings.
More about Caris Life Sciences.

Featured Subspecialty Expert

Guy M. Lindberg, MD

Director of Clinician Interactions